Case Report

An Asian Patient with Myoclonus-Dystonia (DYT11) Responsive to Deep Brain Stimulation of the Globus Pallidus Internus

Akinori Uruha,1,2 Katsuo Kimura,1,3 and Ryoichi Okiyama1

1 Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, Fuchu, Tokyo 183-0042, Japan
2 Department of Clinical Development, Translational Medical Center, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan
3 Department of Clinical Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan

Correspondence should be addressed to Akinori Uruha; a.uruha@gmail.com

Received 5 December 2013; Accepted 31 December 2013; Published 9 February 2014

Academic Editors: C.-C. Huang and H. Ikeda

Copyright © 2014 Akinori Uruha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We describe the case of a 42-year-old Japanese woman with childhood-onset myoclonus, dystonia, and psychiatric symptoms, including anxiety, phobia, and exaggerated startle response. The diagnosis was confirmed as myoclonus-dystonia (DYT11) by identifying a mutation in the gene encoding e-sarcoglycan. Interestingly, while motor-related symptoms in DYT11 generally improve with alcohol ingestion, the patient’s symptoms were exacerbated by alcohol intake. Her severe and medically intractable symptoms were alleviated by bilateral deep brain stimulation of the globus pallidus internus, with myoclonus and dystonia scores showing 70% improvement after the surgery compared to presurgical scores. This is the first report of a genetically confirmed case of DYT11 in Japan. This paper together with other recent reports collectively demonstrates that DYT11 patients are distributed worldwide, including Asia. Thus, a diagnosis of DYT11 should be considered when clinicians encounter a patient with childhood-onset myoclonus and/or dystonia with psychiatric symptoms, regardless of ethnic background.

1. Introduction

Myoclonus-dystonia is an inherited autosomal dominant movement disorder. Although genetically heterogeneous, most hereditary forms of myoclonus-dystonia are due to mutations in the e-sarcoglycan gene (SGCE) [1]. Myoclonus-dystonia caused by the SGCE mutation is classified as DYT11 (OMIM 159900) and characterized by childhood-onset myoclonus, dystonia, and psychiatric symptoms. The psychiatric symptoms are variable, including anxiety, obsessive-compulsive behaviors, and depression. While many patients with DYT11 have been described in Caucasian population, only a few cases have been reported from other populations [2–6]. Here, we describe the first Japanese patient with genetically confirmed DYT11. Although the patient had severe manifestations of motor symptoms, bilateral deep brain stimulation of the globus pallidus internus (Gpi-DBS) has successfully alleviated them.

2. Case Report

A 42-year-old Japanese woman was admitted to our hospital with complaints of involuntary jerking movements of the trunk and hands. Many of her symptoms appeared in early childhood; these include anxiety, fear, and jerking movements of her hands, which her parents noticed when she was 5 years old. Since then, she has also been easily and intensely startled by abrupt touches and loud sounds. These symptoms have been accompanied by mild torticollis and scoliosis since she was 7 years old, with axial jerks appearing in her teenage years. Furthermore, she developed an extreme fear of showing the involuntary movements to others, thus limiting her social interactions. Motor symptoms developed gradually, but, by the age of 40, she was severely disabled and unable to properly perform daily living activities such as eating, drinking, and writing. In the past, several clinicians had tried prescribing psychotropic drugs to treat what they
believed was a psychiatric disorder rather than a movement disorder, hoping that by alleviating the psychiatric symptoms the motor symptoms might also improve. However, these drugs had no effect on any of her motor symptoms.

Upon entering our hospital, neurological examination showed myoclonic movements in axial and shoulder girdle muscles. Additionally, moderate truncal and mild cervical dystonia were seen. Both the myoclonus and dystonia were aggravated by psychological stress. The patient’s scores on the Unified Myoclonus Rating Scale (UMRS) were 29 (rest), 55 (action), 15 (stimulus), and 13 (functional test), while her score on the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) was 14. Alcohol ingestion did not improve, but rather exacerbated, her motor symptoms. Exaggerated startle response was repeatedly observed in response to sudden acoustic and tactile stimuli. Surface electromyographic recordings of the myoclonus showed synchronous activities predominantly in axial and shoulder girdle muscles. There was no electrophysiological evidence of cortical myoclonus. Routine brain magnetic resonance imaging findings showed that the brain was structurally normal. Psychiatric examination demonstrated that she had phobic anxiety disorder with panic attacks.

Direct interviews and physical examinations of the patient’s family members revealed seven affected individuals (Figure 1). The manifestations of symptoms were variable among the family members. Motor symptoms included myoclonus, dystonia, writer’s cramp, and postural tremor. The younger sister (II-3) and the youngest son (III-5) of the proband had psychiatric symptoms: II-3 (40 years) had cervical dystonia, mild action myoclonus in her right hand, and psychiatric symptoms, which were diagnosed as schizophrenia by psychiatrists. She often feels fear. In III-2 (21 years) and III-3 (13 years), cervical dystonia and minimal postural tremor of hands were observed. III-5 (7 years) had cervical and lingual dystonia and water phobia. III-6 (13 years) showed cervical dystonia and mild postural tremor in her upper limbs. The symptoms of the first and third generations were milder than those of the second generation. I-2 (72 years), III-1 (4 years), and III-4 (12 years) do not have any motor or psychiatric symptoms. *: directly examined individual; P: proband; M: myoclonus; D: dystonia; PS: psychiatric symptom; T: postural tremor; WC: writer’s cramp.

As motor symptoms of the proband were severe and medically intractable, bilateral GPi-DBS was performed. The bilateral GPi-DBS improved her motor symptoms remarkably, with both UMRS and BFMDRS scores being about 70% lower 2 months after the operation compared to before the operation. Her postoperative UMRS scores were 9 (rest), 16 (action), 5 (stimulus), and 3 (functional test) on UMRS, while her postsurgical BFMDRS score was 4. Her psychiatric symptoms also seemed to be alleviated postoperatively, although no formal objective assessment was performed. The efficacy of GPi-DBS has been maintained over the 3-year follow-up period.

3. Discussion

The present patient was diagnosed with DYT11, as confirmed by the reported SGCE mutation. Some of the family members also had motor and psychiatric symptoms consistent with DYT11 [6]. Although genetic analysis was not performed on the family members, it is clinically suggested that they are also DYT11 patients. The manifestations of the symptoms in affected family members were variable, and symptoms of the first and third generations were relatively mild compared to those of the second generation. This intrafamilial phenotypic heterogeneity presumably reflects involvement of maternal imprinting, which is known to occur in the human SGCE gene [9].

Alcohol intake improves motor symptoms in most patients with DYT11 [6]. Unexpectedly, the patient in this case showed exacerbated motor symptoms in response to alcohol ingestion. While there is another report of a DYT11 patient showing “alcohol-induced dystonia,” the cause is unclear [10]. It should be noted that the patient in our report cannot inherently drink much alcohol and became inebriated on just the small amount of alcohol administered at the ingestion test. There is a possibility that heavy drinking may rather exacerbate motor symptoms in DYT11, although this is a speculation based only on a single case.

Bilateral GPi-DBS is considered an effective treatment for DYT11, with patients showing >50–80% improvement in both dystonia and myoclonus scores [6, 11]. Although...
DBS of the ventral intermediate thalamic nucleus (Vim) has also been reported to be effective, there are less stimulation-induced adverse events with GPi-DBS compared to Vim-DBS [12]. Thus, GPi-DBS seems to be a preferable therapeutic option. Additionally, the successful result of GPi-DBS in the present patient is encouraging for the use of GPi-DBS as a treatment option for patients with severe DYTI1. The exact mechanisms underlying the success of GPi-DBS for DYTI1 are not well understood, even though there is some anecdotal electrophysiological evidence showing the synchronization of pallidal local field potentials and electromyographic activities during spontaneous dystonic and myoclonic movements [13, 14].

To our knowledge, this is the first genetically confirmed case of DYTI1 in Japan. This case together with other recent reports collectively demonstrates that DYTI1 patients are distributed worldwide, including Asia [2–6]. Thus, DYTI1 should be considered as a differential diagnosis when clinicians encounter a patient with childhood-onset myoclonus and/or dystonia with psychiatric symptoms, regardless of ethnic background.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments
The authors thank Dr. Yasuko Aoki and Dr. Fusako Yokochi at the Department of Neurology, Tokyo Metropolitan Neurological Hospital (TMNH), Japan, Dr. Kazuhiko Ishii, Dr. Yuiko Kimura, Dr. Ayako Isoo, Dr. Takashi Kawasaki, and Dr. Makoto Taniguchi at the Department of Neurosurgery, TMNH, and Dr. Arata Sato at the Department of Psychiatry, TMNH, for medical examination and treatment; and Dr. Sachiko Kamada at the Department of Neurology, Akita University, Japan, and Dr. Itaru Toyoshima at the Department of Neurology, Akita National Hospital, National Hospital Organization, Japan, for analysis of the ε-sarcoglycan gene.

References
[1] A. Zimprich, M. Grabowski, F. Asmus et al., “Mutations in the gene encoding ε-sarcoglycan cause myoclonus-dystonia syndrome,” Nature Genetics, vol. 29, no. 1, pp. 66–69, 2001.
[2] E. J. Chung, W. Y. Lee, J.-Y. Kim et al., “Novel SGCE gene mutation in a Korean patient with myoclonus-dystonia with unique phenotype mimicking Moya-Moya disease,” Movement Disorders, vol. 22, no. 8, pp. 1206–1207, 2007.
[3] V. Borges, P. D. C. Aguiar, H. B. Ferraz, and L. J. Ozelius, “Novel and de novo mutations of the SGCE gene in Brazilian patients with myoclonus-dystonia,” Movement Disorders, vol. 22, no. 8, pp. 1208–1209, 2007.
[4] X.-P. Chen, Y.-W. Zhang, S.-S. Zhang et al., “A novel mutation of the ε-sarcoglycan gene in a Chinese family with myoclonus-dystonia syndrome,” Movement Disorders, vol. 23, no. 10, pp. 1472–1475, 2008.
[5] C.-L. Huang, M.-Y. Lan, Y.-Y. Chang et al., “Large SGCE deletion contributes to Taiwanese myoclonus-dystonia syndrome,” Parkinsonism & Related Disorders, vol. 16, no. 9, pp. 585–589, 2010.
[6] K. Kinugawa, M. Vidailhet, F. Clot, E. Apartis, D. Grabli, and E. Roze, “Myoclonus-dystonia: an update,” Movement Disorders, vol. 24, no. 4, pp. 479–489, 2009.
[7] F. Asmus, A. Zimprich, S. T. Du Montcel et al., “Myoclonus-dystonia syndrome: ε-sarcoglycan mutations and phenotype,” Annals of Neurology, vol. 52, no. 4, pp. 489–492, 2002.
[8] L. Cif, E. M. Valente, S. Hemm et al., “Deep brain stimulation in myoclonus-dystonia syndrome,” Movement Disorders, vol. 19, no. 6, pp. 724–727, 2004.
[9] B. Müller, K. Hedrich, N. Kock et al., “Evidence that paternal expression of the ε-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia,” The American Journal of Human Genetics, vol. 71, no. 6, pp. 1303–1311, 2002.
[10] K. Tedroff, A. Rolfs, and A. Norling, “A novel SGCE gene mutation causing myoclonus dystonia in a family with an unusual phenotype,” Acta Paediatrica, vol. 101, no. 2, pp. e90–e92, 2012.
[11] J. Azoulay-Zyss, E. Roze, M.-L. Welter et al., “Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to ε-sarcoglycan mutations: a pilot study,” Archives of Neurology, vol. 68, no. 1, pp. 94–98, 2011.
[12] D. Gruber, A. A. Kühn, T. Schoenecker et al., “Pallidal and thalamic deep brain stimulation in myoclonus-dystonia,” Movement Disorders, vol. 25, no. 11, pp. 1733–1743, 2010.
[13] X. Liu, I. C. Griffin, S. G. Parkin et al., “Involvement of the medial pallidum in focal myoclonic dystonia: a clinical and neurophysiological case study,” Movement Disorders, vol. 17, no. 2, pp. 346–353, 2002.
[14] E. M. J. Foncke, L. J. Bour, J. D. Speelman, J. H. T. M. Koelman, and M. A. J. Tijssen, “Local field potentials and oscillatory activity of the internal globus pallidus in myoclonus-dystonia,” Movement Disorders, vol. 22, no. 5, pp. 369–376, 2007.